Full View

Cost-effectiveness of oral anticoagulants for ischemic stroke prophylaxis among nonvalvular atrial fibrillation patients

A Shah, A Shewale, CJ Hayes, BC Martin - Stroke, 2016 - Am Heart Assoc
Background and Purpose—The objective of the study is to compare the cost-effectiveness of
oral anticoagulants among atrial fibrillation patients at an increased stroke risk. Methods—A …
被引用次数：77 相关文章
[PDF] archive.org

[PDF][PDF] Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients

BC Martin - Stroke, 2016 - scholar.archive.org
Methods We developed a Markov model to evaluate the cost-effectiveness of dabigatran
(150 mg BID), rivaroxaban (20 mg QD), apixaban (5 mg Background and Purpose—The …

Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients

A Shah, A Shewale, CJ Hayes, BC Martin - Stroke, 2016 - pubmed.ncbi.nlm.nih.gov
Background and purpose The objective of the study is to compare the cost-effectiveness of
oral anticoagulants among atrial fibrillation patients at an increased stroke risk. Methods A …

Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients.

A Shah, A Shewale, CJ Hayes, BC Martin - Stroke, 2016 - europepmc.org
Background and purpose The objective of the study is to compare the cost-effectiveness of
oral anticoagulants among atrial fibrillation patients at an increased stroke risk. Methods A …

Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients

BC Martin - Stroke, 2016 - Am Heart Assoc
Methods We developed a Markov model to evaluate the cost-effectiveness of dabigatran
(150 mg BID), rivaroxaban (20 mg QD), apixaban (5 mg Background and Purpose—The …